Weekly oral alendronic acid in male osteoporosis

Medicine and Dentistry

• Placebo 100%
• Alendronic Acid 58%
• Bone Density 41%
• Therapeutic Procedure 33%
• Male Osteoporosis 25%
• Adverse Event 16%
• Lumbar Spine 16%
• Fracture 16%
• Biochemical Marker 16%
• Bone Turnover 16%
• Patient 16%
• Spine 16%
• Isotopes of Calcium 8%
• Body Mass Index 8%
• Femoral Neck 8%
• Colecalciferol 8%
• Age 8%
• Man 8%
• Incidence 8%
• Hip 8%
• Amaurosis 8%
• Male 8%
• Hip Bone 8%
• Vitamin D 8%

INIS

• bone mineral density 41%
• spine 33%
• males 33%
• osteoporosis 25%
• patients 16%
• bones 16%
• fractures 16%
• comparative evaluations 8%
• men 8%
• weight 8%
• height 8%
• calcium 8%
• vitamin d 8%

Pharmacology, Toxicology and Pharmaceutical Science

• Alendronic Acid 58%
• Adverse Event 16%
• Fracture 16%
• Biochemical Marker 16%
• Tolerability 8%
• Cholecalciferol 8%
• Calcium 8%
• Incidence 8%
• Blindness 8%
• Vitamin D 8%